Physician profile
Brian Snelling
NPI 1730478447
$10,018,598.67
in general payments reported to CMS, 2019-2025
24 companies · $7,486 in 2025
The $7,486 reported for 2025 was more than what 83% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.69 · 2020: $3.5M · 2021: $1.1M · 2022: $1.5M · 2023: $2.7M · 2024: $1.2M · 2025: $7,486.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Acquisitions: $3.8M · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $37K · Travel and Lodging: $8,846 · Consulting Fee: $6,646 · Food and Beverage: $2,311 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Acquisitions | $3,821,124.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $37,108.00 |
| Travel and Lodging | $8,845.80 |
| Consulting Fee | $6,646.00 |
| Food and Beverage | $2,310.69 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,528,426.93 | 2021-2025 | Rist, Pipeline, Unid_pass |
| Medtronic USA, INC. | $3,481,432.73 | 2020 | |
| Medical Device Business Services, INC. | $6,646.00 | 2023 | Pulsar Vascular Pulserider Aneurysm Neck Reconstruction Device, Cerenovus Enterprise |
| Stryker Corporation | $763.30 | 2021-2025 | Target, Surpass Evolve, Neuroform Atlas |
| Baxter Healthcare | $266.37 | 2021-2025 | Floseal, Perclot |
| Microvention, INC. | $174.94 | 2020-2025 | Web Aneurysm Embolization System |
| Kaneka Medical America LLC | $152.31 | 2025 | Apheresis Machine |
| Monteris Medical Corporation | $139.00 | 2023 | Neuroblate |
| Emd Serono, INC. | $91.05 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $76.43 | 2020-2021 | |
| Abbvie INC. | $66.51 | 2023-2024 | Botox |
| Imperative Care, INC | $58.77 | 2022 | |
| Csl Behring | $48.52 | 2020-2024 | Kcentra |
| Pacira Pharmaceuticals Incorporated | $47.40 | 2025 | Exparel |
| Integra Lifesciences Corporation | $34.86 | 2023 | Cusa Clarity, Codman Hakim, Duraseal Exact Spinal Sealant System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $33.23 | 2022-2023 | Zeposia |
| Omniscient Neurotechnology America LTD | $26.19 | 2023 | Quicktome |
| Greenwich Biosciences, INC. | $23.75 | 2021 | |
| Viz.Ai, INC. | $21.76 | 2021 | |
| Akcea Therapeutics, INC. | $15.93 | 2020 | |
| Alexion Pharmaceuticals, INC. | $15.75 | 2019 | |
| Merz North America, INC. | $13.05 | 2019 | |
| Siemens Medical Solutions USA, INC. | $12.04 | 2019 | |
| Alnylam Pharmaceuticals INC. | $11.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Snelling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.